Journal of Literature Pharmacy Sciences

Monoklonal Antikorların Romatizmal Hastalıklardaki Yeri: Geleneksel Derleme
The Place of Monoclonal Antibodies in Rheumatic Diseases: Traditional Rewiew
Şeydanur AVCIa , Alperen CANPOLATa,b, Elif ÇADIRCIa
aAtatürk Üniversitesi Tıp Fakültesi, Tıbbi Farmakoloji AD, Erzurum, Türkiye
bAğrı İbrahim Çeçen Üniversitesi Eczacılık Fakültesi, Farmakoloji AD, Ağrı, Türkiye
J Lit Pharm Sci. 2024;13(2):69-84
doi: 10.5336/pharmsci.2023-100409
Article Language: TR
Full Text
ÖZET
 Çeşitli hastalıklarda tercih edilen ilaçların artık etkisiz kalmasıyla birlikte, bu ilaçların yerine monoklonal antikorlar önemli bir terapötik ajan sınıfı olarak ortaya çıkmıştır. Monoklonal antikorların çoğu onkolojik, immünolojik ve bulaşıcı hastalıklarda kullanılmalarının yanı sıra; diğer hastalık alanlarında kullanımı da gün geçtikçe daha da yaygınlaşmaktadır. Monoklonal antikorların kullanıldığı başta gelen alanlardan bir tanesi de romatizmal hastalıklardır. Romatizmal hastalıklarda, öncelikli tedavi steroit olmayan antiinflamatuar ilaçlar, kortikosteroidler ve hastalık modifiye eden antiromatizmal ilaçlar ile gerçekleştirilmektedir. Daha yakın zamanlarda, çeşitli romatizmal hastalıklarda önemli rol oynayan birincil sitokinler ve inflamatuar yollar üzerinde etki gösteren monoklonal antikorlar ve biyoteknolojik ajanlar geliştirilmiştir. Bu önemli ajanlar arasında, tümör nekroz faktör antagonistleri, antisitokinler ve diğer majör immünsupresif ajanlar yer almaktadır. Bu derlemede en sık görülen romatizmal hastalıklarda, yeni geliştirilen monoklonal antikorların tercihi, kullanılan monoklonal antikorların hedef yolakları, kullanımı ve vücut üzerindeki etkinlikleri ve advers etkilerine değinilmiştir. Diğer birçok ilaçta olduğu gibi monoklonal antikorlarda da farklı sistemleri etkileyen advers etkiler meydana gelebilmektedir. Bu advers etkiler arasında, bağışıklığın baskılanmasından kaynaklı gelişen sekonder enfeksiyonlar yer almaktadır. Hastalığın kritik oluşuna dair verilen bu bilgileri göz ardı ederek monoklonal antikorlarla tedaviye devam edilmesi tartışılması gereken bir konudur. Kar-zarar durumu hesaba katılarak uygulamanın sürdürülmesine karar verilmelidir.

Anahtar Kelimeler: Monoklonal antikorlar; romatoid artrit; sistemik lupus eritematozus; Behçet hastalığı; Sjögren sendromu
ABSTRACT
 Monoclonal antibodies have emerged as an important class of therapeutic agents in today's market as the drugs of choice for various diseases are no longer effective. The majority of monoclonal antibodies are used in oncological, immunological and infectious diseases, but the use of many of these therapeutics is expanding into other disease areas. One of the main areas where monoclonal antibodies are used is rheumatic diseases. The primary treatment of rheumatic diseases is with non steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatismal agents. More recently, monoclonal antibodies and biologics have been developed that act on primary cytokines and inflammatory pathways that play an important role in various rheumatic diseases. These important agents include tumour necrosis factor antagonists, anticytokines and other major immunosuppressive agents. In this review, the preference of newly developed monoclonal antibodies in the most common rheumatic diseases, the target pathways of the monoclonal antibodies used, their use, their efficacy and adverse effects on the body were evaluated. As with many other drugs, adverse effects affecting different systems occur in monoclonal antibodies. The most important of these adverse effects are secondary infections that develop due to immunosuppression. Continuing treatment with monoclonal antibodies by ignoring all this information about the criticality of the disease is an issue that needs to be discussed. It should be decided to continue the treatment by taking into account the cost-benefit situation.

Keywords: Monoclonal antibodies; rheumatoid arthritis; systemic lupus erythematosus; Behçet's disease; Sjögren's syndrome
REFERENCES:
  1. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188-96. [Crossref]  [PubMed] 
  2. Liu JK. The history of monoclonal antibody development-Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-6. [Crossref]  [PubMed]  [PMC] 
  3. Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010;31(9):1198-207. [Crossref]  [PubMed]  [PMC] 
  4. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. [Crossref]  [PubMed]  [PMC] 
  5. Selimoğlu SM, Kasap M, Akpınar G, Karadenizli A. Monoklonal antikor teknolojisinin dünü, bugünü ve geleceği [Yesterday, today and the future of monoclonal antibody technology]. Kocaeli Üniversitesi Sağlık Bilimleri Dergisi. 2016;2(1):6-14. [Crossref] 
  6. Singh R, Chandley P, Rohatgi S. Recent advances in the development of monoclonal antibodies and next-generation antibodies. Immunohorizons. 2023;7(12):886-97. [Crossref]  [PubMed]  [PMC] 
  7. Lim KK, Ng K, Balachandran S, Russell MD, Boalch A, Sinclair A, Coker B, et al. Measuring the impact of monoclonal antibody therapies. Front Med (Lausanne). 2023;10:1256712. [Crossref]  [PubMed]  [PMC] 
  8. Calle E, Gómez-Puerta JA. The spectrum of rheumatic diseases. Handbook of Systemic Autoimmune Diseases. 2018;15:1-13. [Crossref] 
  9. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-72. [Crossref]  [PubMed] 
  10. Mariani FM, Martelli I, Pistone F, Chericoni E, Puxeddu I, Alunno A. Pathogenesis of rheumatoid arthritis: one year in review 2023. Clin Exp Rheumatol. 2023;41(9):1725-34. [Crossref]  [PubMed] 
  11. Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023;82(10):1286-95. [Crossref]  [PubMed] 
  12. Tanaka Y, Takeuchi T, Haaland D, Hall S, Inanc N, Li Z, et al. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials. Int J Rheum Dis. 2023;26(7):1248-59. [Crossref]  [PubMed] 
  13. Takeuchi T, Chino Y, Kawanishi M, Nakanishi M, Watase H, Mano Y, et al. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther. 2023;25(1):60. [Crossref]  [PubMed]  [PMC] 
  14. Keam SJ. Ozoralizumab: first approval. Drugs. 2023;83(1):87-92. [Crossref]  [PubMed] 
  15. Durmuş B. Yeni Anti-TNF'ler: Golimumab ve Sertolizumab Pegol. Turkiye Klinikleri Physical Medicine Rehabilitation-Special Topics. 2014;7(4):81-7.
  16. Lee YH, Song GG. Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis. Z Rheumatol. 2023;82(2):114-22. English. [Crossref]  [PubMed] 
  17. Pappas DA, O'Brien J, Guo L, Shan Y, Baker JF, Kricorian G, et al. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. Arthritis Res Ther. 2023;25(1):166. [Crossref]  [PubMed]  [PMC] 
  18. Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned? BioDrugs. 2024;38(1):61-71. [Crossref]  [PubMed]  [PMC] 
  19. Lee YH, Song GG. Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials. Z Rheumatol. 2024;83(Suppl 1):107-14. English. [Crossref]  [PubMed] 
  20. Leng X, Tang X, Hu P, Guan X, Li Q, Huang C, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: a phase Ia randomized placebo-controlled study. Front Immunol. 2023;13:1110992. [Crossref]  [PubMed]  [PMC] 
  21. Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Chen S, Yang Y, et al. Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase iia trial. Arthritis Rheumatol. 2023;75(6):879-89. [Crossref]  [PubMed] 
  22. Tuttle J, Drescher E, Simón-Campos JA, Emery P, Greenwald M, Kivitz A, et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388(20):1853-62. [Crossref]  [PubMed] 
  23. Clarke SLN, Mageean KS, Carlton H, Simonini G, Sharp GC, Relton CL, et al. "Environmental risk factors associated with juvenile idiopathic arthritis associated uveitis: a systematic review of the literature". J Ophthalmic Inflamm Infect. 2021;11(1):15. [Crossref]  [PubMed]  [PMC] 
  24. Sudhakar M, Kumar S. Juvenile Idiopathic Arthritis. Indian J Pediatr. 2024. [Crossref]  [PubMed] 
  25. Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135. [Crossref]  [PubMed]  [PMC] 
  26. Brunello F, Tirelli F, Pegoraro L, Dell'Apa F, Alfisi A, Calzamatta G, et al. New Insights on Juvenile Psoriatic Arthritis. Front Pediatr. 2022;10:884727. [Crossref]  [PubMed]  [PMC] 
  27. Van Gelder RN. Drug Costs, Effectiveness, and Kids in the crossfire: adalimumab in juvenile ıdiopathic arthritis-associated uveitis. Ophthalmology. 2019;126(3):425-7. [Crossref]  [PubMed] 
  28. Padda IS, Bhatt R, Parmar M. Golimumab. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [PubMed] 
  29. Akioka S. Interleukin-6 in juvenile idiopathic arthritis. Mod Rheumatol. 2019;29(2):275-86. [Crossref]  [PubMed] 
  30. Adrovic A, Yildiz M, Köker O, Şahin S, Barut K, Kasapçopur Ö. Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review. Arch Rheumatol. 2020;36(1):146-57. [Crossref]  [PubMed]  [PMC] 
  31. Liu DW, Chen JJ, Tang XM, Zhang Y, Zhou J. Infliximab therapy and outcomes in patients with polyarticular juvenile idiopathic arthritis: a single-center study in China. World J Pediatr. 2020;16(1):68-73. [Crossref]  [PubMed] 
  32. Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2020;20(7):725-40. [Crossref]  [PubMed] 
  33. Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, Ruiz C, Costela-Ruiz VJ. Infectious processes and systemic lupus erythematosus. Immunology. 2019;158(3):153-60. [Crossref]  [PubMed]  [PMC] 
  34. Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82(8):999-1014. [Crossref]  [PubMed] 
  35. McKeon KP, Jiang SH. Treatment of systemic lupus erythematosus. Aust Prescr. 2020;43(3):85-90. [Crossref]  [PubMed]  [PMC] 
  36. Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus-Focus on lupus nephritis. Hum Vaccin Immunother. 2022;18(5):2072143. [Crossref]  [PubMed]  [PMC] 
  37. Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative effectiveness of rituximab and common ınduction therapies for lupus nephritis: a systematic review and network meta-analysis. Front Immunol. 2022;13:859380. [Crossref]  [PubMed]  [PMC] 
  38. Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, et al. Impact of belimumab on organ damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2022;74(11):1822-8. [Crossref]  [PubMed]  [PMC] 
  39. Kirou KA, Dall Era M, Aranow C, Anders HJ. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13:980079. [Crossref]  [PubMed]  [PMC] 
  40. van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Gordon RM, Fei K, et al. Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase ii open-label extension study. J Rheumatol. 2022;49(4):380-7. [Crossref]  [PubMed] 
  41. Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a Phase II, randomized, double-blind, placebo-controlled Trial. Arthritis Rheumatol. 2023;75(2):242-52. [Crossref]  [PubMed]  [PMC] 
  42. Askanase A, Khalili L, Tang W, Mertz P, Scherlinger M, Sebbag E, et al. New and future therapies: changes in the therapeutic armamentarium for SLE. Best Pract Res Clin Rheumatol. 2023:101865. [Crossref]  [PubMed] 
  43. Jayne DR, Steffgen J, Romero-Diaz J, Bajema I, Boumpas DT, Noppakun K, et al. Clinical and Biomarker responses to BI 655064, an antagonistic Anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, Phase II trial. Arthritis Rheumatol. 2023;75(11):1983-93. [Crossref]  [PubMed] 
  44. Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, Phase 2 trial. Arthritis Rheumatol. 2023;75(12):2185-94. [Crossref]  [PubMed] 
  45. Rovin BH, Furie RA, Ross Terres JA, Giang S, Schindler T, Turchetta A, et al. Kidney Outcomes And Preservation Of Kidney Function With Obinutuzumab In Patients With Lupus Nephritis: A Post Hoc Analysis Of The NOBILITY Trial. Arthritis Rheumatol. 2024;76(2):247-54. [Crossref]  [PubMed] 
  46. Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med. 2023;29(8):2041-7. [Crossref]  [PubMed]  [PMC] 
  47. Vehof J, Utheim TP, Bootsma H, Hammond CJ. Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome. Clin Exp Rheumatol. 2020;38 Suppl 126(4):301-9. [PubMed] 
  48. Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9-25. [Crossref]  [PubMed]  [PMC] 
  49. Jonsson R, Brokstad KA, Jonsson MV, Delaleu N, Skarstein K. Current concepts on Sjögren's syndrome-classification criteria and biomarkers. Eur J Oral Sci. 2018;126 Suppl 1(Suppl Suppl 1):37-48. [Crossref]  [PubMed]  [PMC] 
  50. Shen L, He J, Kramer JM, Bunya VY. Sjögren's syndrome: animal models, etiology, pathogenesis, clinical subtypes, and diagnosis. J Immunol Res. 2019;2019:8101503. [Crossref]  [PubMed]  [PMC] 
  51. Chen YH, Wang XY, Jin X, Yang Z, Xu J. Rituximab therapy for primary sjögren's syndrome. Front Pharmacol. 2021;12:731122. [Crossref]  [PubMed]  [PMC] 
  52. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129. [Crossref]  [PubMed]  [PMC] 
  53. Cornec D, Jousse-Joulin S, Costa S, Marhadour T, Marcorelles P, Berthelot JM, et al. High-grade salivary-gland involvement, assessed by histology or ultrasonography, is associated with a poor response to a single rituximab course in primary sjögren's syndrome: data from the tears randomized trial. PLoS One. 2016;11(9):e0162787. [Crossref]  [PubMed]  [PMC] 
  54. Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary sjögren's syndrome. Arthritis Rheumatol. 2017;69(7):1440-50. Erratum in: Arthritis Rheumatol. 2020;72(10):1748. [Crossref]  [PubMed] 
  55. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526-31. [Crossref]  [PubMed] 
  56. De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015;54(12):2249-56. [Crossref]  [PubMed] 
  57. Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399(10320):161-71. [Crossref]  [PubMed] 
  58. Clark HJ, Fong PCC, Ng KPL. Clinical and serological resolution of pembrolizumab associated Sjögren's syndrome: long-term follow-up. Rheumatology (Oxford). 2021;61(1):e22-e4. [Crossref]  [PubMed] 
  59. Muralidharan S, Njenga M, Garron T, Bondensgaard K, Paolini JF. Preclinical Immunopharmacologic assessment of KPL-404, a novel, humanized, non-depleting antagonistic anti-CD40 monoclonal antibody. J Pharmacol Exp Ther. 2022;381(1):12-21. [Crossref]  [PubMed] 
  60. Berardicurti O, Pavlych V, Cola ID, Ruscitti P, Di Benedetto P, Navarini L, et al. Long-term safety of rituximab in primary sjögren syndrome: the experience of a single center. j rheumatol. 2022;49(2):171-5. [Crossref]  [PubMed] 
  61. Pontarini E, Sciacca E, Grigoriadou S, Rivellese F, Lucchesi D, Fossati-Jimack L, et al. NKp30 receptor upregulation in salivary glands of sjögren's syndrome characterizes ectopic lymphoid structures and Is restricted by rituximab treatment. Front Immunol. 2021;12:706737. [Crossref]  [PubMed]  [PMC] 
  62. Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. JCI Insight. 2022;7(23):e163030. [Crossref]  [PubMed]  [PMC] 
  63. Lamprecht P. Revidierte chapel-hill-nomenklatur der vaskulitiden [Revised chapel hill nomenclature of vasculitides]. Z Rheumatol. 2012;71(9):743-4. German. [Crossref]  [PubMed] 
  64. Cheng L, Zhan H, Liu Y, Chen H, Zhang F, Zheng W, et al. Infectious agents and pathogenesis of Behçet's disease: an extensive review. Clin Immunol. 2023;251:109631. [Crossref]  [PubMed] 
  65. Manuelyan Z, Butt E, Parupudi S. Gastrointestinal Behçet's disease: manifestations, diagnosis, and management. Dis Mon. 2024;70(1S):101674. [Crossref]  [PubMed] 
  66. Barroso-García N, Atienza-Mateo B, Ferraz-Amaro I, Prieto-Peña D, Beltrán E, Adán A, et al. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients. Semin Arthritis Rheum. 2023;58:152153. [Crossref]  [PubMed] 
  67. Hatemi G, Tukek NB, Esatoglu SN, Ozguler Y, Taflan SS, Uygunoglu U, et al. Infliximab for vascular involvement in Behçet's syndrome. Clin Immunol. 2023;253:109682. [Crossref]  [PubMed] 
  68. van der Houwen TB, Humer B, Missotten TO, Thiadens AAHJ, van Hagen PM, van Laar JAM. Long-term data on efficacy and safety of adalimumab in Behçet's disease. Clin Immunol. 2023;247:109242. [Crossref]  [PubMed] 
  69. Yu J, Shin SJ, Park YJ, Kim HW, Lee BI, Ye BD, et al. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea. BMC Gastroenterol. 2023;23(1):449. [Crossref]  [PubMed]  [PMC] 
  70. Yang S, Huang Z, Liu X, Li H, Xie L, Chen X, et al. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis. Int Immunopharmacol. 2021;93:107430. [Crossref]  [PubMed] 
  71. De Simone L, Invernizzi A, Aldigeri R, Mastrofilippo V, Marvisi C, Gozzi F, et al. Effectiveness of infliximab and interferon alpha-2a for the treatment of behçet's uveitis: customizing therapy according to the clinical features. Ocul Immunol Inflamm. 2022;30(2):506-14. [Crossref]  [PubMed] 
  72. Zou J, Cai JF, Ye JF, Guan JL. Tofacitinib as an alternative therapy for refractory intestinal Behçet's syndrome. Ther Adv Musculoskelet Dis. 2022;14:1759720X221124014. [Crossref]  [PubMed]  [PMC] 
  73. Gopaluni S, Smith R, Goymer D, Cahill H, Broadhurst E, Wallin E, et al. Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE). Arthritis Res Ther. 2022;24(1):81. [Crossref]  [PubMed]  [PMC] 
  74. Zhong H, Liu T, Liu Y, Zhang X, Zhou Y, Su Y. Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China. Rheumatology (Oxford). 2022;61(7):2923-30. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com